Atea Pharmaceuticals financials
$5.18−0.38%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$35.1M | -$48.0M | -$54.9M | -$45.6M | -$41.3M | -$39.0M | -$39.0M | -$37.2M | -$46.9M | -$69.8M | -$46.6M | -$40.8M |
| Net income | -$32.9M | -$45.4M | -$44.9M | -$42.0M | -$37.2M | -$34.3M | -$33.5M | -$31.2M | -$40.5M | -$63.2M | -$39.2M | -$33.1M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.41 | $-0.57 | $-0.58 | $-0.53 | $-0.44 | $-0.40 | $-0.40 | $-0.37 | $-0.48 | $-0.75 | $-0.47 | $-0.40 |
| EBITDA | -$35.0M | -$47.9M | -$54.8M | -$45.5M | -$41.2M | -$38.9M | -$38.9M | -$37.1M | -$46.8M | -$69.7M | -$46.5M | -$40.8M |
| Operating cash flow | -$37.1M | -$46.4M | -$28.2M | -$40.4M | -$32.9M | -$30.6M | -$30.4M | -$23.0M | -$42.2M | -$39.9M | -$21.8M | $0.00 |
| Free cash flow | -$37.1M | -$46.4M | -$28.2M | -$40.4M | -$32.9M | -$30.6M | -$30.4M | -$23.0M | -$42.2M | -$39.9M | -$21.8M | $0.00 |
| Diluted shares | 80.1M | 79.2M | 78.0M | 79.1M | 83.7M | 85.2M | 84.5M | 84.4M | 84.3M | 83.9M | 83.4M | 83.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $76.5M | $79.3M | $95.7M | $77.3M | $87.7M | $119.4M |
| Short-term investments | $142.9M | $176.7M | $206.1M | $252.0M | $292.0M | $306.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $232.3M | $267.1M | $315.2M | $343.0M | $391.6M | $440.0M |
| Total liabilities | $28.1M | $33.4M | $39.8M | $27.2M | $27.2M | $28.9M |
| Shareholders' equity | $204.2M | $233.7M | $275.4M | $315.8M | $364.4M | $411.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology